New Drug Combo Involving Ketamine Shows Promise for Bipolar Depression

FDA: No CV advantage with naproxen
FDA: No CV advantage with naproxen
A combination of the drugs D-cycloserine and lurasidone may prolong the antidepressant effects of ketamine, according to a small study.

NeuroRx, Inc., a clinical phase pharmaceutical company, reports first-in-man efficacy data for a newly-purposed class of drugs targeted towards rapidly reducing symptoms of depression and suicidality in patients with bipolar disorder and maintaining that effect over time. The peer-reviewed open label study in eight patients, elements of which were published in the Journal of Clinical Psychiatry, demonstrated a 50% reduction in symptoms of depression and a 75% reduction in suicidality in patients with treatment-resistant bipolar depression.

While the use of ketamine for rapid reversal of depression is known, though not yet approved by FDA, its effect is known to be short-lived. This is the first clinical report showing that the ketamine effect can potentially be sustained for two months with additional agents.

READ FULL ARTICLE Curated publisher From PR Newswire